S. Desmonde and . Editing, We thank the MONOD ANRS 12206 trial independent data monitoring committee meeting: Dominique Costagliola (Chair Mark Cotton (Cape Town, Diana Gibb) and Elisabeth Menu Désiré Dahourou PhD was funded by the ANRS (ANRS12206-B89). Malik Coulibaly PhD was funded by EDCTP-ANRS-LIH

S. Abobo-avocatier-fatoumata-koné, H. Menan, T. Toni, and V. Yapo, Programme National de Prise en Charge Community representatives, Pharmacie de la Santé Publique: Carine Kodo. Implementers: Touré Siaka, Pety Touré (ACONDA), Fassinou Ekouevi (EGPAF) Programme National de Santé Infantile: Dorothée Koumi. Programme Elargi de Vaccination: Berté Koné. Methodology and Data Management Center: Inserm U897 Carole Devaux

B. Bazin, M. De-solère, and C. Rekacewicz, The content is solely the responsibility of the authors and does not necessarily represent the official views of the French Inserm-ANRS

M. Project, Centre de Recherche Internationale pour la Santé

H. Immunology and R. Unit, Côte d'Ivoire. 13 Paediatric Department 15 UMR 1058, Pathogenesis and control of chronic infections, Inserm, Inserm, issue.16, p.17

U. The-gap and . Report, ISBN 978-92-9253-062-4 Geneva: UNAIDS; 2014, pp.1-422, 2014.

M. Newell, H. Coovadia, M. Cortina-borja, N. Rollins, P. Gaillard et al., Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis, The Lancet, vol.364, issue.9441, pp.1236-1279, 2004.
DOI : 10.1016/S0140-6736(04)17140-7

A. Violari, M. Cotton, D. Gibb, A. Babiker, J. Steyn et al., Early Antiretroviral Therapy and Mortality among HIV-Infected Infants, New England Journal of Medicine, vol.359, issue.21, pp.2233-2277, 2008.
DOI : 10.1056/NEJMoa0800971

P. Palumbo, J. Lindsey, M. Hughes, M. Cotton, R. Bobat et al., Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure, New England Journal of Medicine, vol.363, issue.16, pp.1510-1530, 2010.
DOI : 10.1056/NEJMoa1000931

A. Violari, J. Lindsey, M. Hughes, H. Mujuru, L. Barlow-mosha et al., Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children, New England Journal of Medicine, vol.366, issue.25, pp.2380-2389, 2012.
DOI : 10.1056/NEJMoa1113249

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443859

P. Yeni, Rapport du Groupe d'Experts 2008 sur la prise en charge médicale des patients infectées par le VIH, sous la direction du Pr Patrick Yeni, p.409, 2008.

A. Ciaranello, K. Doherty, M. Penazzato, J. Lindsey, L. Harrison et al., Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age, AIDS, vol.29, issue.10, pp.1247-59, 2015.
DOI : 10.1097/QAD.0000000000000672

A. Pau, N. Moodley, D. Holland, H. Fomundam, G. Matchaba et al., Instability of lopinavir/ritonavir capsules at ambient temperatures in sub-Saharan Africa: relevance to WHO antiretroviral guidelines, AIDS, vol.19, issue.11, pp.1233-1237, 2005.
DOI : 10.1097/01.aids.0000176227.01850.9e

Y. Ren, J. Nuttall, C. Egbers, B. Eley, T. Meyers et al., Effect of Rifampicin on Lopinavir Pharmacokinetics in HIV-Infected Children With Tuberculosis, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.47, issue.5, pp.566-575, 2008.
DOI : 10.1097/QAI.0b013e3181642257

B. Larru, J. Eby, and E. Lowenthal, Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz, Pediatric Health Med Ther, vol.5, pp.29-42, 2014.

D. Hirt, S. Urien, M. Olivier, H. Peyriere, B. Nacro et al., Is the Recommended Dose of Efavirenz Optimal in Young West African Human Immunodeficiency Virus-Infected Children?, Antimicrobial Agents and Chemotherapy, vol.53, issue.10, pp.4407-4420, 2009.
DOI : 10.1128/AAC.01594-08

F. Rouet, D. Ekouevi, M. Chaix, M. Burgard, A. Inwoley et al., Transfer and Evaluation of an Automated, Low-Cost Real-Time Reverse Transcription-PCR Test for Diagnosis and Monitoring of Human Immunodeficiency Virus Type 1 Infection in a West African Resource-Limited Setting, Journal of Clinical Microbiology, vol.43, issue.6, pp.2709-2726, 2005.
DOI : 10.1128/JCM.43.6.2709-2717.2005

G. Piaggio, D. Elbourne, S. Pocock, S. Evans, D. Altman et al., Reporting of Noninferiority and Equivalence Randomized Trials, JAMA, vol.308, issue.24, pp.2594-604, 2012.
DOI : 10.1001/jama.2012.87802

B. Jones, P. Jarvis, J. Lewis, and A. Ebbutt, Trials to assess equivalence: the importance of rigorous methods, BMJ, vol.313, issue.7048, pp.36-45, 1996.
DOI : 10.1136/bmj.313.7048.36

D. Dahourou, M. Amorissani-folquet, M. Coulibaly, D. Avit-edi, N. Meda et al., Missed opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment before the age of two in West Africa, J Int AIDS Soc, vol.19, issue.1, p.20601, 2011.

A. Bosse, C. Dahourou, D. Malateste, K. , M. Coulibaly et al., Virological response and resistances over 12 months among HIV?infected children less than 2 years receiving first-line lopinavir /ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort, J Int AIDS Soc, 2017.

A. Coovadia, E. Abrams, R. Stehlau, T. Meyers, L. Martens et al., Reuse of Nevirapine in Exposed HIV-Infected Children After Protease Inhibitor???Based Viral Suppression, JAMA, vol.304, issue.10, pp.1082-90, 2010.
DOI : 10.1001/jama.2010.1278

A. Coovadia, E. Abrams, R. Strehlau, S. Shiau, F. Pinillos et al., Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa, JAMA, vol.314, issue.17, pp.1808-1825, 2015.
DOI : 10.1001/jama.2015.13631

L. Van-de-wijer, A. Schellekens, D. Burger, J. Homberg, Q. De-mast et al., Rethinking the risk???benefit ratio of efavirenz in HIV-infected children, The Lancet Infectious Diseases, vol.16, issue.5, pp.76-81, 2016.
DOI : 10.1016/S1473-3099(16)00117-1

E. Arrive, M. Newell, D. Ekouevi, M. Chaix, R. Thiebaut et al., Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis, International Journal of Epidemiology, vol.36, issue.5, pp.1009-1030, 2007.
DOI : 10.1093/ije/dym104

URL : https://hal.archives-ouvertes.fr/inserm-00187308

J. Fogel, Q. Li, T. Taha, D. Hoover, N. Kumwenda et al., Initiation of Antiretroviral Treatment in Women After Delivery Can Induce Multiclass Drug Resistance in Breastfeeding HIV-Infected Infants, Clinical Infectious Diseases, vol.52, issue.8, pp.1069-76, 2011.
DOI : 10.1093/cid/cir008

C. Zeh, P. Weidle, L. Nafisa, H. Lwamba, J. Okonji et al., HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis, PLoS Medicine, vol.20, issue.3, p.1000430, 2011.
DOI : 10.1371/journal.pmed.1000430.s001

A. Babiker, H. Castro-nee-green, A. Compagnucci, S. Fiscus, C. Giaquinto et al., First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial, Lancet Infect Dis, vol.11, issue.4, pp.273-83, 2011.

M. Coulibaly, N. Meda, C. Yonaba, S. Ouedraogo, M. Congo et al., Missed Opportunities for Early Access to Care of HIV-Infected Infants in Burkina Faso, PLoS ONE, vol.346, issue.10, p.111240, 2014.
DOI : 10.1371/journal.pone.0111240.s001

D. Avit, M. Folquet-amorissani, C. Amani-bosse, J. Eliam-kouakou, V. Mea-assande et al., Access to early infant diagnosis and antiretroviral therapy in Abidjan, Côte d'Ivoire, 21st Conference on Retroviruses and Opportunistic Infections, pp.2011-2013, 2014.

M. Penazzato, P. Revill, A. Prendergast, I. Collins, S. Walker et al., Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all?, The Lancet Infectious Diseases, vol.14, issue.7, pp.650-655, 2014.
DOI : 10.1016/S1473-3099(13)70262-7

A. Ciaranello, J. Park, L. Ramirez-avila, K. Freedberg, R. Walensky et al., Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions, BMC Medicine, vol.336, issue.Suppl 1, p.59, 2011.
DOI : 10.1056/NEJM199705083361901

URL : https://hal.archives-ouvertes.fr/inserm-00605913

C. Ndondoki, H. Brou, T. Konan, M. Oga, M. et al., Universal HIV Screening at Postnatal Points of Care: Which Public Health Approach for Early Infant Diagnosis in C??te d'Ivoire?, PLoS ONE, vol.28, issue.8, p.67996, 2013.
DOI : 10.1371/journal.pone.0067996.t003

P. Musoke, A. Szubert, V. Musiime, K. Nathoo, P. Nahirya-ntege et al., Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years, AIDS, vol.29, issue.13, pp.1623-1655, 2015.
DOI : 10.1097/QAD.0000000000000749

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833198

A. Kekitiinwa, V. Musiime, M. Thomason, G. Mirembe, M. Lallemant et al., Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children, Antiviral Therapy, vol.21, issue.7, pp.579-85, 2016.
DOI : 10.3851/IMP3054

W. Dehority, J. Abadi, A. Wiznia, and R. Viani, Use of Integrase Inhibitors in HIV-Infected Children and Adolescents, Drugs, vol.68, issue.3, pp.1483-97, 2015.
DOI : 10.1007/s40265-015-0446-2